These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Detection and follow-up of early arteriosclerotic vascular lesions]. Rudofsky G; Meyer P; Hirche H; Altenhoff B; Lohman A Vasa Suppl; 1987; 20():165-8. PubMed ID: 3321492 [No Abstract] [Full Text] [Related]
25. Hemorrheological, micro- and macrocirculatory effects of naftidrofuryl in an acute study: a randomized, placebo-controlled, double-blind individual comparison. Jung F; Kiesewetter H; Mrowietz C; Leipnitz G; Braun B; Wappler M; Scheffler P; Wenzel E Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):507-14. PubMed ID: 3679623 [TBL] [Abstract][Full Text] [Related]
26. [Clinical aspects and therapy of sudden deafness. Data of a patient sample of the ear, nose, throat clinic of the Wiesbaden City Clinic 1974-1982]. Zastrow G; Arndt HJ Laryngol Rhinol Otol (Stuttg); 1987 May; 66(5):237-41. PubMed ID: 3613774 [TBL] [Abstract][Full Text] [Related]
27. The immediate effects of naftidrofuryl on the human electrocochleogram in Ménière's disorder. Gibson WP; Ramsden RT; Moffat DA J Laryngol Otol; 1977 Aug; 91(8):679-96. PubMed ID: 894121 [No Abstract] [Full Text] [Related]
28. [Early detection and modification of preclinical arteriosclerosis]. Rudofsky G Vasa Suppl; 1990; 30():21-4. PubMed ID: 2075574 [No Abstract] [Full Text] [Related]
29. [Sudden deafness--on the age dependence of therapy results with reference to naftidrofuryl (Dusodril)]. Koehn W; Nickol HJ HNO; 1985 Jan; 33(1):36-9. PubMed ID: 3972647 [TBL] [Abstract][Full Text] [Related]
30. [Naftidrofuryl. (Pralixene)]. Naess K Tidsskr Nor Laegeforen; 1980 Mar; 100(8-9):518-9. PubMed ID: 7385216 [No Abstract] [Full Text] [Related]
32. [Transcutaneous measures of oxygen partial pressure and capillaroscopic parameters as affected by naftidrofuryl in patients with obliterative arteriopathies, Fontaine stages II-IV]. Ranft J; Heidrich H; Lammersen T J Mal Vasc; 1987; 12(1):78-81. PubMed ID: 3559415 [TBL] [Abstract][Full Text] [Related]
33. [Therapy of algodystrophy (Sudeck disease) with naftidrofuryl hydrogen oxalate (NH)]. Mayer M; Strosche H; Bachmann H Unfallchirurg; 1986 Mar; 89(3):117-20. PubMed ID: 2422761 [No Abstract] [Full Text] [Related]
34. New daily aspirin guidelines address age, sex differences. Mayo Clin Womens Healthsource; 2009 Sep; 13(9):3. PubMed ID: 19652638 [No Abstract] [Full Text] [Related]
35. The therapeutic uses of naftidrofuryl (Praxilene)--cerebrovascular disease. Judge TG Scott Med J; 1978 Jan; 23(1):43-4. PubMed ID: 635539 [No Abstract] [Full Text] [Related]
36. [Naftidrofuryl--a new direction in angiologic therapy. Symposium of the 17th annual meeting of the German Society of Angiology. Esslingen, 1988]. Vasa Suppl; 1988; 24():1-75. PubMed ID: 3212597 [No Abstract] [Full Text] [Related]
37. [Medico-social importance and therapeutic measures in vascular diseases. Opinion of Prof. G. Guagliano]. Guagliano G Minerva Cardioangiol; 1974 May; 22(5):388-9. PubMed ID: 4465748 [No Abstract] [Full Text] [Related]
38. [Aspirin for primary prevention of asymptomatic atherosclerosis]. Lévesque H J Mal Vasc; 2002 Dec; 27(5):263-6. PubMed ID: 12525771 [No Abstract] [Full Text] [Related]
39. Therapeutic use of naftidrofuryl (Praxilene)--peripheral vascular disease. Forrest H Scott Med J; 1978 Jan; 23(1):45-6. PubMed ID: 635540 [No Abstract] [Full Text] [Related]
40. [Secondary prevention of arteriosclerosis]. Hoffmann U; Leu AJ Praxis (Bern 1994); 1996 Sep; 85(39):1201-5. PubMed ID: 8927904 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]